loading page

Anti-il-5 in pediatric allergic diseases
  • +1
  • Laura Tenero,
  • Elisa Arturi,
  • Michele Piazza,
  • Giorgio Piacentini
Laura Tenero
University of Verona

Corresponding Author:[email protected]

Author Profile
Elisa Arturi
Università di Verona
Author Profile
Michele Piazza
Universita' di Verona, Clinica Pediatrica
Author Profile
Giorgio Piacentini
Università di Verona
Author Profile


Interleukin (IL)-5 is a potent mediator of the inflammatory cascade in the allergic response.Its predominant role in atopic reactions makes this cytokine an ideal target for blocking the eosinophilic inflammatory hyper-responsiveness to allergens. The management of allergic diseases in childhood – such as severe asthma, atopic dermatitis, and eosinophilic esophagitis - is a challenge. In particular, there are concerns regarding the use of high-dose corticosteroids. Over the last few years, biologics targeting IL-5 or IL-5 receptor - that are mepolizumab, reslizumab, and benralizumab - represent a new, promising, and more personalized therapeutic option.
07 Aug 2020Submitted to Pediatric Allergy and Immunology
30 Aug 2020Editorial Decision: Accept